Pneumococcal Vaccination Protocol for Adults
All adults aged ≥50 years should receive a single dose of pneumococcal conjugate vaccine (PCV21, PCV20, or PCV15) if they have never received a PCV or their vaccination history is unknown, with adults aged 19-49 years requiring vaccination only if they have specific medical conditions or risk factors. 1, 2
Age-Based Recommendations
Adults Aged ≥50 Years (Universal Recommendation)
- Administer one dose of PCV21, PCV20, or PCV15 if PCV-naïve or vaccination history unknown 1, 2
- If PCV15 is chosen, follow with PPSV23 ≥1 year later (minimum 8 weeks for immunocompromised patients, those with cochlear implants, or CSF leaks) 3
- This represents a 2024 expansion from the previous age threshold of ≥65 years 2
Adults Aged 19-49 Years (Risk-Based Only)
Vaccinate only if the following conditions are present:
- Immunocompromising conditions (HIV, malignancy, immunosuppressive therapy, solid organ transplant)
- Functional or anatomic asplenia
- CSF leak or cochlear implant
- Chronic medical conditions (chronic heart/lung/liver disease, diabetes, alcoholism, smoking) 3, 1
Vaccination by Previous Immunization History
No Prior Pneumococcal Vaccine or PCV7 Only
- Single dose of PCV21, PCV20, or PCV15
- If PCV15 used: add PPSV23 ≥1 year later (≥8 weeks for high-risk groups) 3
PPSV23 Only Previously
- Single dose of PCV21, PCV20, or PCV15 administered ≥1 year after last PPSV23 3
PCV13 Only Previously
- For adults ≥65 years: PCV21, PCV20, or PPSV23 ≥1 year after PCV13 (≥8 weeks for high-risk groups when using PPSV23) 3
- For high-risk adults 19-64 years: Same timing as above 3
PCV13 + PPSV23 at Age <65 Years
- Single dose of PCV21, PCV20, or PPSV23
- If using PCV21/PCV20: administer ≥5 years after last pneumococcal vaccine
- If using PPSV23: administer ≥1 year after PCV13 (≥8 weeks for high-risk) AND ≥5 years after previous PPSV23 3
PCV13 + PPSV23 at Age ≥65 Years (Series Complete)
- Shared clinical decision-making regarding additional PCV21 or PCV20
- If administered: give ≥5 years after last pneumococcal vaccine dose 3
High-Risk Groups Requiring Special Protocols
Immunocompromised, CSF Leak, or Cochlear Implant (Ages 19-64)
Use shortened intervals:
- PCV15 followed by PPSV23 at ≥8 weeks (not 1 year) 3
- If PCV13 previously given, PPSV23 at ≥8 weeks 3
- These patients may require two PPSV23 doses separated by ≥5 years 3
Solid Organ Transplant Recipients
- Follow immunocompromised protocol above
- Consider high-dose or adjuvanted influenza vaccines (ages 19-64 on immunosuppression) 1
Key Clinical Pitfalls to Avoid
Don't miss the age expansion: The threshold dropped from ≥65 to ≥50 years in 2024—many adults aged 50-64 without risk factors now qualify 2
Interval errors: The most common mistake is using 1-year intervals for high-risk patients when 8-week intervals are appropriate for PCV-to-PPSV23 transitions 3
Incomplete series: When PCV15 is chosen, PPSV23 must follow—this is not optional 3
Overlooking prior PCV13 recipients: Adults who received only PCV13 years ago still need additional vaccination, particularly those now ≥65 years 3
Serotype 4 considerations: In populations where ≥30% of pneumococcal disease is serotype 4, PCV20 or PCV15+PPSV23 may provide better coverage than PCV21 3
Vaccine Selection Guidance
All three PCVs (PCV15, PCV20, PCV21) are acceptable options with the following considerations:
- PCV20 or PCV21 alone: Single-dose convenience, no need for PPSV23 follow-up
- PCV15 + PPSV23: Broader serotype coverage (23 vs 20-21 serotypes) but requires two-dose series 3, 4
- PCV21 is the newest option (2024) and can be used interchangeably with PCV20 in most scenarios 3
Coadministration
Pneumococcal vaccines may be administered simultaneously with other age-appropriate vaccines (including COVID-19, influenza, RSV) at the same visit unless specific contraindications exist 3